Original Publication Date: 1 June, 2015
Publication / Source: Future Oncology
Authors: Francesca Fenizia, Antonella De Luca, Raffaella Pasquale et al.
The presence of EGFR mutations predicts the sensitivity to EGF receptor (EGFR)-tyrosine kinase inhibitors in a molecularly defined subset of non-small-cell lung carcinoma (NSCLC) patients. For this reason, EGFR testing of NSCLC is required to provide personalized treatment options and better outcomes for NSCLC patients. As surgery specimens are not available in the majority of NSCLC, other currently available DNA sources are small biopsies and cytological samples, providing however limited and low-quality material.
This article is being featured as part of our Spotlight on circulating tumor cells – visit our Spotlight homepage for more information.